VKTX News and Press, Viking Therapeutics Inc. From 06/05/24

2024-06-05 09:00:17 ET Summary Structure Therapeutics Inc.'s oral GLP-1 agonist, GSBR-1290, showed a 6.2% mean weight loss over 12 weeks, significantly outperforming placebo. Adverse events were high, with 89.2% experiencing nausea and 62.2% vomiting. The financial outlook is ...

2024-06-05 08:10:19 ET More on Eli Lilly Eli Lilly and Company (LLY) Lilly Oncology ASCO Investor Event (Transcript) Eli Lilly's Growth And Challenges: A Cautious Buy Eli Lilly: Addressing Supply Challenges Should Accelerate Growth Eli Lilly CFO Anat Ashkenaz...

2024-06-04 15:40:11 ET More on Viking Therapeutics What Makes Viking Therapeutics An Attractive Takeover Target Or Big Pharma Partner Viking Therapeutics: The Metabolic Masterpiece Primed To Be Acquired Viking Therapeutics, Inc. (VKTX) Q1 2024 Earnings Call Transcrip...

2024-06-04 13:59:40 ET Viking Therapeutics Inc (NASDAQ: VKTX) is in focus today after announcing positive Phase 2b data for its treatment for biopsy-confirmed non-alcoholic steatohepatitis (NASH). $VKTX’s drug did significantly better than placebo VK2809 of the biotech fi...

2024-06-04 09:22:09 ET More on related stocks Intel's Goldman Sach's Meeting Yields Interesting Information Intel: Capitalize On The Downtrend Computex Chronicles Part 2: AMD Leaps Into Copilot+ PCs And Outlines Infrastructure GPU Roadmap Nvidia, DraftKings, ...

2024-06-04 08:07:00 ET More on Viking Therapeutics What Makes Viking Therapeutics An Attractive Takeover Target Or Big Pharma Partner Viking Therapeutics: The Metabolic Masterpiece Primed To Be Acquired Viking Therapeutics, Inc. (VKTX) Q1 2024 Earnings Call Transcrip...

Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) PR Newswire Up to 75% of Patients Treated with VK2809 Achieved NASH Resolution with No Worsening of Fibros...

2024-06-03 10:15:00 ET Even if you're not an investor like Cathie Wood, who specializes in businesses that claim to have a shot at disrupting their industries, investing in aspiring disruptors can be a great tactic to shore up your portfolio's exposure to growth. Assuming you can tolerate t...

2024-06-02 10:00:00 ET More on Amgen, Structure Therapeutics, etc. Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? ...

2024-05-31 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips There are plenty of underappreciated stocks on the market. Look at Viking Therapeutics (NASDAQ: VKTX ), for example. When I first highlighted VKTX on June 22, 2023 , it ...